Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database.

Sandberg-Wollheim M, Neudorfer O, Grinspan A, Weinstock-Guttman B, Haas J, Izquierdo G, Riley C, Ross AP, Baruch P, Drillman T, Coyle PK.

Int J MS Care. 2018 Jan-Feb;20(1):9-14. doi: 10.7224/1537-2073.2016-079.

2.

Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis.

Traboulsee AL, Cornelisseª P, Sandberg-Wollheim M, Uitdehaag BM, Kappos L, Jongen PJ, Constantinescu CS, di Cantogno EV, Li DK.

Mult Scler J Exp Transl Clin. 2016 Sep 6;2:2055217316666406. doi: 10.1177/2055217316666406. eCollection 2016 Jan-Dec.

3.

Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Yes.

Sandberg-Wollheim M, Olsson T.

Mult Scler. 2013 May;19(6):714-6. doi: 10.1177/1352458513480011. No abstract available.

PMID:
23658235
4.

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings.

Sandberg-Wollheim M, Kornmann G, Bischof D, Moraga MS, Hennessy B, Alteri E.

Mult Scler. 2011 Apr;17(4):431-40. doi: 10.1177/1352458511403642.

PMID:
21486902
5.

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS.

Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.

6.

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.

Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V.

Ther Adv Neurol Disord. 2011 Jan;4(1):3-14. doi: 10.1177/1756285610391693.

7.

Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy.

Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G.

Mult Scler. 2011 Apr;17(4):423-30. doi: 10.1177/1352458510394610. Epub 2011 Jan 10.

PMID:
21220368
8.

Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command.

Freedman MS, Cohen B, Dhib-Jalbut S, Jeffery D, Reder AT, Sandberg-Wollheim M, Weinstock-Guttman B.

Curr Med Res Opin. 2009 Oct;25(10):2459-70. doi: 10.1185/03007990903158364. Review.

PMID:
19678753
9.

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.

Lancet Neurol. 2009 Jun;8(6):519-29. doi: 10.1016/S1474-4422(09)70085-7. Epub 2009 May 4.

PMID:
19409854
10.

Cognitive dysfunction 24-31 years after isolated optic neuritis.

Nilsson P, Rorsman I, Larsson EM, Norrving B, Sandberg-Wollheim M.

Mult Scler. 2008 Aug;14(7):913-8. doi: 10.1177/1352458508090669. Epub 2008 Jun 23.

PMID:
18573827
11.

Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease.

Bodil Roth E, Theander E, Londos E, Sandberg-Wollheim M, Larsson A, Sjöberg K, Stenberg P.

Scand J Immunol. 2008 Jun;67(6):626-31. doi: 10.1111/j.1365-3083.2008.02115.x.

12.

The role of MRI of the brain and spinal cord, and CSF examination for the diagnosis of primary progressive multiple sclerosis.

Nilsson P, Sandberg-Wollheim M, Norrving B, Larsson EM.

Eur J Neurol. 2007 Nov;14(11):1292-5. Epub 2007 Aug 31.

PMID:
17764461
13.

A follow-up study of Nordic multiple sclerosis candidate gene regions.

Datta P, Harbo HF, Ryder LP, Akesson E, Benedikz J, Celius EG, Andersen O, Myhr KM, Sandberg-Wollheim M, Hillert J, Svejgaard A, Sorensen PS, Spurkland A, Oturai A.

Mult Scler. 2007 Jun;13(5):584-9. Epub 2007 Feb 9.

PMID:
17548436
14.

Health-related quality of life in secondary progressive multiple sclerosis.

Beiske AG, Naess H, Aarseth JH, Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Sandberg-Wollheim M, Sorensen PS, Myhr KM; Nordic SPMS study group.

Mult Scler. 2007 Apr;13(3):386-92.

PMID:
17439908
15.

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.

Neurology. 2006 Sep 26;67(6):944-53.

PMID:
17000959
16.

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS.

Ann Neurol. 2005 Dec;58(6):840-6. Review.

PMID:
16283615
17.

Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis.

Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, Stam-Moraga M, Chang P, Francis GS.

Neurology. 2005 Sep 27;65(6):802-6. Epub 2005 Aug 10. Review.

PMID:
16093457
18.

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.

Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S; European Interferon Beta-1a IM Dose-Comparison Study Investigators.

Neurology. 2005 Jul 12;65(1):40-7.

PMID:
16009883
19.

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G; EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group.

Arch Neurol. 2005 May;62(5):785-92.

PMID:
15883267
20.

Interferon-beta1a treatment for multiple sclerosis.

Sandberg-Wollheim M.

Expert Rev Neurother. 2005 Jan;5(1):25-34. Review.

PMID:
15853471
21.

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T; Laquinimod in Relapsing MS Study Group.

Neurology. 2005 Mar 22;64(6):987-91.

PMID:
15781813
22.

Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up.

Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M.

J Neurol. 2005 Apr;252(4):396-402. Epub 2005 Mar 22.

PMID:
15778816
23.

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study.

Sandberg-Wollheim M, Bever C, Carter J, Färkkilä M, Hurwitz B, Lapierre Y, Chang P, Francis GS; EVIDENCE Study Group.

J Neurol. 2005 Jan;252(1):8-13.

PMID:
15654549
24.

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.

Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, Sandberg-Wollheim M, Soelberg Sørensen P.

J Neurol Neurosurg Psychiatry. 2004 May;75(5):706-10.

25.

Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis.

Harbo HF, Lie BA, Sawcer S, Celius EG, Dai KZ, Oturai A, Hillert J, Lorentzen AR, Laaksonen M, Myhr KM, Ryder LP, Fredrikson S, Nyland H, Sørensen PS, Sandberg-Wollheim M, Andersen O, Svejgaard A, Edland A, Mellgren SI, Compston A, Vartdal F, Spurkland A.

Tissue Antigens. 2004 Mar;63(3):237-47.

PMID:
14989713
26.
27.

Factors influencing analysis of prolyl endopeptidase in human blood and cerebrospinal fluid: increase in assay sensitivity.

Momeni N, Yoshimoto T, Ryberg B, Sandberg-Wollheim M, Grubb A.

Scand J Clin Lab Invest. 2003;63(6):387-95.

PMID:
14594319
28.

Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients.

Harbo HF, Datta P, Oturai A, Ryder LP, Sawcer S, Setakis E, Akesson E, Celius EG, Modin H, Sandberg-Wollheim M, Myhr KM, Andersen O, Hillert J, Sorensen PS, Svejgaard A, Compston A, Vartdal F, Spurkland A.

J Neuroimmunol. 2003 Oct;143(1-2):101-6.

PMID:
14575924
29.

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.

Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators.

Neurology. 2002 Nov 26;59(10):1507-17.

PMID:
12451189
30.

A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis.

Akesson E, Oturai A, Berg J, Fredrikson S, Andersen O, Harbo HF, Laaksonen M, Myhr KM, Nyland HI, Ryder LP, Sandberg-Wollheim M, Sorensen PS, Spurkland A, Svejgaard A, Holmans P, Compston A, Hillert J, Sawcer S.

Genes Immun. 2002 Aug;3(5):279-85.

31.

International consensus statement on the use of disease-modifying agents in multiple sclerosis.

Freedman MS, Blumhardt LD, Brochet B, Comi G, Noseworthy JH, Sandberg-Wollheim M, Soelberg SP; Paris Workshop Group.

Mult Scler. 2002 Feb;8(1):19-23.

PMID:
11936483
32.

Linkage analysis suggests a region of importance for multiple sclerosis in 3p14-13.

Dai Y, Xu C, Holmberg M, Oturai A, Fredrikson S, Sandberg-Wollheim M, Laaksonen M, Spurkland A, Myhr KM, Ryder LP, Sorensen PS, Svejgaard A, Hillert J.

Genes Immun. 2001 Dec;2(8):451-4.

33.

Serological differences in monozygotic twin pairs discordant for multiple sclerosis.

Bergkvist M, Sandberg-Wollheim M.

Acta Neurol Scand. 2001 Nov;104(5):262-5.

PMID:
11696018
34.

The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis.

Dai KZ, Harbo HF, Celius EG, Oturai A, Sørensen PS, Ryder LP, Datta P, Svejgaard A, Hillert J, Fredrikson S, Sandberg-Wollheim M, Laaksonen M, Myhr KM, Nyland H, Vartdal F, Spurkland A.

Genes Immun. 2001 Aug;2(5):263-8.

35.

No linkage or association of the nitric oxide synthase genes to multiple sclerosis.

Modin H, Dai Y, Masterman T, Svejgaard A, Sørensen PS, Oturai A, Ryder LP, Spurkland A, Vartdal F, Laaksonen M, Sandberg-Wollheim M, Myhr KM, Nyland H, Hillert J.

J Neuroimmunol. 2001 Sep 3;119(1):95-100.

PMID:
11525805
36.

Analysis of an interferon-gamma gene dinucleotide-repeat polymorphism in Nordic multiple sclerosis patients.

Dai Y, Masterman T, Huang WX, Sandberg-Wollheim M, Laaksonen M, Harbo HF, Oturai A, Ryder LP, Soelberg-Sørensen P, Svejgaard A, Hillert J.

Mult Scler. 2001 Jun;7(3):157-63.

PMID:
11475438
37.

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS.

Ann Neurol. 2001 Jul;50(1):121-7.

PMID:
11456302
38.

Tumour necrosis factor microsatellites and HLA-DRB1*, HLA-DQA1*, and HLA-DQB1* alleles in Peruvian patients with rheumatoid arthritis.

Castro F, Acevedo E, Ciusani E, Angulo JA, Wollheim FA, Sandberg-Wollheim M.

Ann Rheum Dis. 2001 Aug;60(8):791-5.

39.

Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q.

Larsen F, Oturai A, Ryder LP, Madsen HO, Hillert J, Fredrikson S, Sandberg-Wollheim M, Laaksonen M, Harbo HF, Sawcer S, Fugger L, Sorensen PS, Svejgaard A.

Genes Immun. 2000 Oct;1(7):456-9.

40.

Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis.

Oturai A, Larsen F, Ryder LP, Madsen HO, Hillert J, Fredrikson S, Sandberg-Wollheim M, Laaksonen M, Koch-Henriksen N, Sawcer S, Fugger L, Sorensen PS, Svejgaard A.

Ann Neurol. 1999 Oct;46(4):612-6.

PMID:
10514098
41.

Golli-MBP gene in multiple sclerosis susceptibility.

Tienari PJ, Kuokkanen S, Pastinen T, Wikström J, Sajantila A, Sandberg-Wollheim M, Palo J, Peltonen L.

J Neuroimmunol. 1998 Jan;81(1-2):158-67.

PMID:
9521617
42.

Tumour necrosis factor microsatellite alleles in an Italian population.

Ciusani E, Salmaggi A, Pocio F, Nespolo A, Sandberg-Wollheim M.

Eur J Immunogenet. 1997 Feb;24(1):9-13.

PMID:
9043872
43.

No genetic linkage between multiple sclerosis and the interferon alpha/beta locus.

Bergkvist M, Martinsson T, Aman P, Sandberg-Wollheim M.

J Neuroimmunol. 1996 Apr;65(2):163-5.

PMID:
8964898
44.

An evaluation of tumor necrosis factor microsatellite alleles in genetic susceptibility to multiple sclerosis.

Sandberg-Wollheim M, Ciusani E, Salmaggi A, Pociot F.

Mult Scler. 1995 Nov;1(3):181-5.

PMID:
9345451
45.

Analysis of HLA-class II DQA1, DQB1, DRB1 and DPB1 in Italian multiple sclerosis patients.

Ciusani E, Allen M, Sandberg-Wollheim M, Eoli M, Salmaggi A, Milanese C, Nespolo A, Gyllensten U.

Eur J Immunogenet. 1995 Apr;22(2):171-8.

PMID:
7605774
46.

Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.

Sandberg-Wollheim M, Hommes OR, Hughes RA, Paty DW, Abdul-Ahad AK.

Mult Scler. 1995;1 Suppl 1:S48-50.

PMID:
9345399
47.

Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles.

Allen M, Sandberg-Wollheim M, Sjögren K, Erlich HA, Petterson U, Gyllensten U.

Hum Immunol. 1994 Jan;39(1):41-8.

PMID:
8181961
48.
49.

Antigen processing gene polymorphisms in HLA-DR2 multiple sclerosis.

Liblau R, van Endert PM, Sandberg-Wollheim M, Patel SD, Lopez MT, Land S, Fugger L, McDevitt HO.

Neurology. 1993 Jun;43(6):1192-7.

PMID:
7909590
50.

Primary Sjögren's syndrome in patients with multiple sclerosis.

Sandberg-Wollheim M, Axéll T, Hansen BU, Henricsson V, Ingesson E, Jacobsson L, Larsson A, Lieberkind K, Manthorpe R.

Neurology. 1992 Apr;42(4):845-7.

PMID:
1565240

Supplemental Content

Loading ...
Support Center